254 related articles for article (PubMed ID: 30385715)
21. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
22. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
[TBL] [Abstract][Full Text] [Related]
23. Regulation of Mertk Surface Expression via ADAM17 and γ-Secretase Proteolytic Processing.
Lahey KC; Varsanyi C; Wang Z; Aquib A; Gadiyar V; Rodrigues AA; Pulica R; Desind S; Davra V; Calianese DC; Liu D; Cho JH; Kotenko SV; De Lorenzo MS; Birge RB
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673989
[TBL] [Abstract][Full Text] [Related]
24. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
Hu Y; Revenko A; Barsoumian H; Bertolet G; Fowlkes NW; Maazi H; Green MM; He K; Sezen D; Voss TA; Leyton CSK; Masrorpour F; Rafiq Z; Puebla-Osorio N; Leuschner C; MacLeod R; Cortez MA; Welsh JW
J Exp Clin Cancer Res; 2024 Mar; 43(1):70. PubMed ID: 38443968
[TBL] [Abstract][Full Text] [Related]
26. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
[TBL] [Abstract][Full Text] [Related]
27. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
[TBL] [Abstract][Full Text] [Related]
28. MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.
Triantafyllou E; Pop OT; Possamai LA; Wilhelm A; Liaskou E; Singanayagam A; Bernsmeier C; Khamri W; Petts G; Dargue R; Davies SP; Tickle J; Yuksel M; Patel VC; Abeles RD; Stamataki Z; Curbishley SM; Ma Y; Wilson ID; Coen M; Woollard KJ; Quaglia A; Wendon J; Thursz MR; Adams DH; Weston CJ; Antoniades CG
Gut; 2018 Feb; 67(2):333-347. PubMed ID: 28450389
[TBL] [Abstract][Full Text] [Related]
29. Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC.
Giroud P; Renaudineau S; Gudefin L; Calcei A; Menguy T; Rozan C; Mizrahi J; Caux C; Duong V; Valladeau-Guilemond J
Front Immunol; 2020; 11():564133. PubMed ID: 33101282
[TBL] [Abstract][Full Text] [Related]
30. Non-conventional Inhibitory CD4
Zappasodi R; Budhu S; Hellmann MD; Postow MA; Senbabaoglu Y; Manne S; Gasmi B; Liu C; Zhong H; Li Y; Huang AC; Hirschhorn-Cymerman D; Panageas KS; Wherry EJ; Merghoub T; Wolchok JD
Cancer Cell; 2018 Jun; 33(6):1017-1032.e7. PubMed ID: 29894689
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-10 receptor signaling promotes the maintenance of a PD-1
Hanna BS; Llaó-Cid L; Iskar M; Roessner PM; Klett LC; Wong JKL; Paul Y; Ioannou N; Öztürk S; Mack N; Kalter V; Colomer D; Campo E; Bloehdorn J; Stilgenbauer S; Dietrich S; Schmidt M; Gabriel R; Rippe K; Feuerer M; Ramsay AG; Lichter P; Zapatka M; Seiffert M
Immunity; 2021 Dec; 54(12):2825-2841.e10. PubMed ID: 34879221
[TBL] [Abstract][Full Text] [Related]
32. The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma.
Shi C; Li X; Wang X; Ding N; Ping L; Shi Y; Mi L; Lai Y; Song Y; Zhu J
J Hematol Oncol; 2018 Mar; 11(1):43. PubMed ID: 29554921
[TBL] [Abstract][Full Text] [Related]
33. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
34. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
35. MerTK activity is not necessary for the proliferation of glioblastoma stem cells.
Hoque M; Wai Wong S; Recasens A; Abbassi R; Nguyen N; Zhang D; Stashko MA; Wang X; Frye S; Day BW; Baell J; Munoz L
Biochem Pharmacol; 2021 Apr; 186():114437. PubMed ID: 33571503
[TBL] [Abstract][Full Text] [Related]
36. PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity.
Koller P; Baran N; Harutyunyan K; Cavazos A; Mallampati S; Chin RL; Jiang Z; Sun X; Lee HH; Hsu JL; Williams P; Huang X; Curran MA; Hung MC; Konopleva M
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793852
[TBL] [Abstract][Full Text] [Related]
37. Lactate acid promotes PD-1
Zhang Y; Huang Y; Hong Y; Lin Z; Zha J; Zhu Y; Li Z; Wang C; Fang Z; Zhou Z; Peng Y; Yu X; Liu L; Xu B
Int Immunopharmacol; 2024 Mar; 130():111765. PubMed ID: 38447414
[TBL] [Abstract][Full Text] [Related]
38. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
39. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
40. The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.
Rodríguez-Rodríguez N; Madera-Salcedo IK; Bugarin-Estrada E; Sánchez-Miranda E; Torres-García D; Cervantes-Torres J; Fragoso G; Rosetti F; Crispín JC; Sciutto E
Clin Immunol; 2020 Mar; 212():108240. PubMed ID: 31299381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]